Medicare increases payments for oncology infusion and begins a one-year demonstration project that pays oncologists to assess the side effects of chemotherapy.
CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.
Also Unclear whether HHS Secretary Tommy Thompson will depart as previously planned.
California approves $3 billion program for stem-cell research.
Oklahoma’s new cigarette tax will provide $7 million a year to the University of Oklahoma Cancer Center.
National Cancer Policy Board will end in 2005, NCI to support a cancer forum at IOM.
Funding opportunities listed.
October issue of Business & Regulatory Report included.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation
- FDA’s OCE publishes three final guidances to increase clinical trial enrollment
